Serge Saxonov, who serves as the Chief Executive Officer of 10x Genomics, Inc. (NASDAQ:TXG), has executed a significant transaction involving the company's equity. On June 22, 2026, Saxonov sold a total of 29,900 shares of Class A Common Stock. The aggregate value of these shares was approximately $1,033,268. These transactions were not ad hoc but were executed under a pre-arranged Rule 10b5-1 trading plan. This specific plan was adopted by Saxonov on November 29, 2025.
The sale was not a single lump-sum transaction but was broken down into multiple trades. The execution prices for these shares ranged from $33.289 to $36.1646 per share. Following the completion of these sales, Saxonov's direct holding in 10x Genomics Class A Common Stock stands at 1,108,380 shares. Beyond direct ownership, Saxonov maintains indirect ownership of Class A Common Stock through several trusts where he serves as trustee. Specifically, he holds 27 shares via the Andromeda Trust, 213,250 shares through the Y/S Descendants’ Trust, and 71,644 shares through the Y/S Pot Trust.
The timing of this insider sale is notable given the current trading environment for TXG. The stock is trading near its 52-week high of $36.59. This position near the high follows a remarkable 197% gain over the past year, according to InvestingPro data. The stock currently trades at $34.62, which gives the company a market capitalization of $4.38 billion. InvestingPro analysis indicates that the stock appears overvalued at current levels relative to its Fair Value. For deeper insights into TXG’s valuation and performance, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.
In the broader context of corporate activity, 10x Genomics has recently announced its acquisition of Proteintech Genomics. This move is designed to enhance the company's capabilities in multimodal analysis and proteomics. The acquisition includes the addition of Proteintech Genomics’ technologies, such as the Human Discovery Panel, which integrates intracellular proteins, cell surface proteins, and transcriptomic profiles. Following this announcement, Canaccord has reiterated its Buy rating on 10x Genomics, maintaining a price target of $32.00.
Furthermore, 10x Genomics has entered into a multi-year research collaboration with Cleveland Clinic. This partnership will focus on studying biomarkers in bladder cancer patients. The collaboration will utilize 10x Genomics’ Flex Apex and Xenium platforms, with potential expansion to its Atera platform. The primary aim of this partnership is to identify biomarkers that may predict patient response to antibody-drug conjugate treatments.
In related market developments, TD Cowen has released data on short interest changes in the life science tools and diagnostics sector. The data notes shifts in companies such as Exagen Inc., Waters Corp., Avantor Inc., and Myriad Genetics Inc. These recent developments highlight 10x Genomics’ strategic moves in expanding its research and technological capabilities.